Keywords: GenVec, Novartis, Research collaboration, Haring loss, Balance disorders

GenVec extends research deal with Novartis

Article | 29 January 2012

Print This

US biopharma company GenVec (Nasdaq: GNVC) says that it has extended its research collaboration and license agreement with Swiss drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in